

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-42. (Canceled)

43. (Currently amended) ~~A pharmaceutical composition comprising:~~

~~(i) an~~ An oligonucleotide consisting of between 10-30 nucleotide units, which contains three adjacently located nucleotide sequences, A, B and C, in the following order (5' to 3'):

A-B-C or C-B-A,

in which

A consists of between 2 and 10 nucleotide units, wherein between 1 and 5 of the nucleotide units in A are locked nucleotide units;

B consists of between 1 and 10 nucleotide units, wherein B comprises nucleotide units selected from the group consisting of 2'-deoxy-erythro-pentofuranosyl, ribo-pentofuranosyl and alpha-L-oxo LNA nucleotide units, wherein B comprises at least one alpha-L-oxo LNA nucleotide unit; and

C consists of between 2 and 10 nucleotides units wherein between 1 and 5 of the nucleotide units in C are locked nucleotide units; ~~and~~

~~(ii) a pharmaceutical carrier.~~

44. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 43, in which B represents a sequence of nucleotide units that makes the oligonucleotide able to recruit RNase H when the oligonucleotide is hybridized to a target RNA molecule.

45. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 44, in which B consists of 2'-deoxy-erythro-pentofuranosyl nucleotide units and alpha-L-oxy LNA nucleotide units.

46. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 45, wherein the locked nucleotide units in A and C are selected from the group consisting of oxy-LNA, thio-LNA and amino-LNA nucleotide units, wherein the LNA nucleotide units are in either the alpha or beta configuration.

47. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 45, wherein the locked nucleotide units in A and C are beta-D-oxy-LNA nucleotide units.

48-53. (Canceled)

54. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 45, wherein A consists of 1, 2, 3, 4 or 5 LNA nucleotide units.

55. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 45, wherein C consists of 2, 3, 4 or 5 LNA nucleotide units.

56. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 54, wherein C consists of 2, 3, 4 or 5 LNA nucleotide units.

57. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 45, wherein the oligonucleotide consists of 10-20 nucleotide units.

58. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** according to claim 45, wherein the oligonucleotide consists of 12-18 nucleotide units.

59. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** according to claim 45, wherein the oligonucleotide consists of 13, 14, 15, 16 or 17 nucleotide units.

60. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** according to claim 45, wherein the oligonucleotide consists of 16 nucleotide units.

61. (Canceled)

62. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** according to claim 45, wherein B consists of 5, 6, 7 or 8 nucleotide units.

63-64. (Canceled)

65. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** according to claim 45, in which the linkages between the nucleotide units in the oligonucleotide comprise at least one linkage which is not a -O-P(O)₂-O- linkage

66. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** **according** to claim 45, in which the linkages between the nucleotide units in B in the oligonucleotide comprises at least one phosphothioate linkage

67. (Currently amended) ~~The pharmaceutical composition~~ **The oligonucleotide** **according to** claim 45, wherein the linkages between the nucleotide units are phosphorothioate internucleoside linkages.

68. (Currently amended) ~~The pharmaceutical composition~~ The oligonucleotide according to claim 45, which further comprises other antisense compounds, chemotherapeutic compounds, antiinflammatory compounds and/or antiviral compounds.

69. (New) A composition comprising an oligonucleotide according to any of claims 43-47, 54-60, 62 and 65-68.

70. (New) A pharmaceutical composition comprising an oligonucleotide according to any of claims 43-47, 54-60, 62 and 65-68 and a pharmaceutically acceptable carrier.